A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and
safe in the treatment of chronic tumor related pain compared to placebo. In addition
tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as
slow release (SR).
*Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to
as extended release (ER) in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Grünenthal GmbH
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.